28 results about "Early Therapy" patented technology

The invention discloses a primer probe group and a kit for joint detection of mycoplasma genitalium, ureaplasma urealyticum and chlamydia trachomatis, and belongs to the technical field of molecular biological detection. The primer probe group comprises a primer probe group A for directly detecting a mycoplasma genitalium mgpB gene, a primer probe group B for directly detecting a ureaplasma urealyticum ureB gene and a primer probe group C for directly detecting a chlamydia trachomatis ompA gene; the kit comprises a PCR (Polymerase Chain Reaction) reaction solution and the primer probe group. Nucleic acid extraction is not needed, the detection cost is greatly reduced, the experiment time is shortened, meanwhile, the specificity and accuracy are still guaranteed, meanwhile, the sensitivity is improved, and the method has wide application prospects in the fields of non-gonococcal genital tract infection main pathogen detection, infertility and prenatal and postnatal care screening and the like. And the kit has important significance on clinical diagnosis, early treatment and prevention of diseases, prevalence and the like.

The invention discloses a method, equipment, a medium and a program product for predicting different progression stages of colorectal cancer. The method is used for predicting different progression stages of colorectal cancer based on the expression quantity of target protein. According to the method, by means of a computer system and equipment, whether a subject suffers from colorectal cancer related diseases or not can be well predicted by detecting the expression level of target protein, different progression stages of the colorectal cancer can be distinguished, a new direction and means are provided for early treatment and effective treatment of the colorectal cancer, and the method is worthy of popularization and application. And the method has practical significance on clinical guidance of colorectal cancer.

The invention provides a marker combination for predicting severe acute pancreatitis and application thereof. Specifically, the invention provides application of a gene, mRNA, cDNA and protein of a risk marker for judging severe acute pancreatitis or a detection reagent of the gene, the mRNA, the cDNA and the protein, and the gene, the mRNA, the cDNA and the protein are used for preparing / establishing a diagnostic reagent or a kit / equipment for judging the occurrence risk of severe acute pancreatitis. Researches show that the severe acute pancreatitis risk marker can be used as a marker for early judgment of whether acute pancreatitis patients develop into severe acute pancreatitis, has high sensitivity and specificity, can quickly diagnose severe acute pancreatitis at a relatively early disease progress stage, and provides powerful assistance for early treatment intervention of diseases.

The invention discloses application of a reagent for detecting a plasma metabolism marker combination in preparation of a product for diagnosing breast cancer, and belongs to the field of breast cancer markers. According to the application of the reagent for detecting the plasma metabolism marker combination in preparing the product for diagnosing the breast cancer, the plasma metabolism marker combination comprises dehydroepiandrosterone sulfate, acylcarnitine 12: 0 and taurodeoxycholic acid. The plasma metabolism marker combination has high specificity, high sensitivity and non-invasiveness when being used for breast cancer detection, so that a subject can conveniently and safely receive detection, and the plasma metabolism marker combination is suitable for screening and detection of large-scale common people and is beneficial to early screening, early diagnosis and early treatment of breast cancer.

A B-cell specific octamer-binding protein 1 super-enhancer ribonucleic acid (BOB1-seRNA) and an application thereof are provided. The nucleotide sequence of the BOB1-seRNA is shown in SEQ ID NO: 1. Through experiments, it further confirms that the BOB1-seRNA is downregulated in patients with coronary heart disease and can be used in preparation of a product for diagnosing or predicting the coronary heart disease. The use of this molecular marker can be used for early diagnosis of the coronary heart disease, which is rapid and effective. It is not only of great significance for early treatment of the coronary heart disease and saving medical costs, but also provides therapeutic targets and important basis for clinical applications such as gene therapy and drug therapy.

The invention discloses a traditional Chinese medicine composition for treating middle and advanced stage tumors. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9-11 parts of ganoderma lucidum slices, 1-3 parts of radix angelicae sinensis, 1-3 parts of cordyceps militaris, 5-7 parts of poria cocos, 1-3 parts of fructus lycii, 2-4 parts of radix astragali, 5-7 parts of polyporus umbellatus, 3-5 parts of ginseng slices and 3-5 parts of exocarpium citri grandis. The traditional Chinese medicine composition has the effects of benefiting qi and nourishing blood, tonifying kidney and spleen, and supporting healthy energy. The traditional Chinese medicine is used for treating qi and blood deficiency syndromes caused by middle and advanced tumors, wherein the syndromes comprise mental exhaustion, limb weakness, body emaciation, pale complexion, inappetence and the like. The traditional Chinese medicine composition can also be used for relieving toxic and side effects after radiotherapy and chemotherapy and early treatment of cancers. The invention further discloses a method for preparing the traditional Chinese medicine composition, the dosage form advantage is remarkable, the preparation process is stable and controllable, and the method is suitable for industrial production.

The application provides application of a modified form of WDHD1, WDHD1 S141 phosphorylation, as a biomarker in preparation of a liver cancer early diagnosis or prognosis reagent. The application also provides a kit for quantitatively or semi-quantitatively detecting a protein, which contains an antibody capable of specifically amplifying the WDHD1 S141 phosphorylation. The application can more effectively preliminarily evaluate and predict the condition of a subject suffering from liver cancer by detecting the expression level of the WDHD1 S141 phosphorylation. The application will help improve the diagnosis accuracy of liver cancer and provide an important basis for early treatment of patients. The kit can be applied to the diagnosis of early, middle and late liver cancer. The application also provides application of the WDHD1 S141 phosphorylation in preparation of a liver cancer treatment drug.

The invention relates to the field of tumor molecular diagnosis and precision medicine, in particular to a model for predicting early chemotherapy failure of a DLBCL patient and application of the model. By detecting the ctDNA concentration level of the patient base line and the early treatment period and / or combining clinical characteristic parameters, a multivariable risk assessment algorithm is established, the high-risk patient can be identified in the early treatment period, a reliable basis is provided for individualized treatment, and remarkable clinical and social values are achieved.

The invention provides a Parkinson's disease freezing gait prediction method and device based on eye movement characteristics, equipment and a medium. The method comprises the following steps: acquiring target information corresponding to a target object; the target information comprises target demographic data, target clinical features and target eyeball motion parameters collected at a certain time point, and / or target demographic data, target clinical features and target eyeball motion parameters continuously collected according to a preset frequency within a preset time; and inputting the target information into the target frozen gait prediction model, so that the frozen gait prediction model analyzes and processes the target information to obtain a static frozen gait risk assessment result and / or a dynamic frozen gait risk assessment result corresponding to the target object. According to the scheme, through multi-dimensional integration and collaborative verification of traditional clinical phenotypes and objective indexes of eye movement, non-invasive efficient evaluation of frozen gait risks is achieved, and objective basis and key technical support can be provided for early diagnosis and early treatment of disease subtypes.

The invention discloses a preparation method of a monoclonal antibody for detecting trichophyton rubrum and application of the monoclonal antibody in fungal skin disease detection, and belongs to the field of biological medicine. The monoclonal antibody provided by the invention only has specific reaction with trichophyton rubrum, and has no cross reaction with common fungi such as trichophyton mentagrophytes, epidermophyton flocculent, candida albicans, malassezia and the like and normal flora of a human body, so that a false positive result is effectively avoided. Based on the double-antibody sandwich principle, the detection sensitivity can reach 200 pg / mL level, trace trichophyton rubrum in a clinical sample can be detected, and the positive rate is obviously higher than that of direct microscopic examination. The whole detection process can be completed within 15-20 min and is far faster than fungus culture for several weeks, a rapid diagnosis basis can be provided for doctors, and early treatment is facilitated. The kit provided by the invention has standardized operation steps, does not need complex instruments and special training, and is suitable for popularization and use in clinical laboratories of hospitals at all levels, outpatient clinics of dermatology and even basic medical institutions.

The application provides a modified form of DEPTOR, DEPTOR K106 lactylation, as a biomarker in the preparation of a test agent for the preliminary evaluation or prediction of liver cancer. The application also provides a kit for quantitatively or semi-quantitatively detecting a protein, which contains an antibody capable of specifically binding to DEPTOR K106 lactylation. The application can more effectively preliminarily evaluate and predict whether a subject has a tumor by detecting the expression level of DEPTOR K106 lactylation. The application will help improve the diagnostic accuracy of liver cancer and provide an important basis for early treatment of patients. The kit of the application can be used for the diagnosis of early, medium and late liver cancer.

The present application belongs to the field of intelligent medical treatment, and particularly relates to a method, device, medium and program product for predicting RMPP based on lung microvessel changes. The method comprises the following steps: S101: acquiring CT images of a pediatric MPP patient; S102: extracting the CT images to obtain quantitative PBV parameters, wherein the quantitative PBV parameters comprise BV10%, wherein BV10% refers to the percentage of blood volume in blood vessels with a cross-sectional area greater than 10 mm2 in total lung blood volume; and S103: if BV10% is higher than a first threshold value, determining that the pediatric MPP patient has a high risk of developing into RMPP, otherwise outputting a prediction result that the pediatric MPP patient has a low risk of developing into RMPP. The present application discovers the prediction effect of microvessel changes in CT on the occurrence and development of RMPP by quantitatively measuring the microvessel changes, realizes the clinical value of early diagnosis of RMPP, and thus drives early treatment in the clinic.

The application discloses a plasma metabolic marker composition and a screening method and application thereof, and relates to the technical field of biomedicine. The plasma metabolic marker composition comprises glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-formic acid and phosphatidylethanolamine 36:2p. The metabolic marker composition is significantly different in different cancer types, can distinguish different cancer types of cancer patients, and realizes the detection of pan-cancer. The metabolic marker composition is non-invasive and minimally invasive when used for the detection of pan-cancer, is more suitable for the screening and detection of a large number of ordinary people, has high sensitivity and specificity, is more suitable for the early screening of cancer, and is helpful for the early screening, early diagnosis and early treatment of cancer, and is helpful for improving the survival rate and cure rate of cancer patients.

The application belongs to the technical field of biomedical detection, and discloses a Raman spectrum analysis device for quantitative detection of blood tumor markers, which comprises a blood collection and centrifugal unit with an adaptive load adjustment mechanism, which is used for real-time monitoring of blood density and composition, and automatic adjustment of centrifugal force and time parameters according to the blood density and composition; a fiber Raman spectrometer equipped with an automatic wavelength calibration system, wherein an ultrafast laser pulse emitter and a high-sensitivity photon counting detector are integrated on the fiber Raman spectrometer; the application enhances the Raman scattering signal by adopting a quantum entangled light source and a nonlinear optical crystal, and can significantly improve the detection capability of low-concentration tumor markers. This improvement enables the device to accurately detect the presence of tumor markers in the early stage of cancer, providing strong support for early treatment of patients.

This invention relates to the field of medical diagnostic technology, specifically providing a urine PCR kit for predicting minimal change disease (MND) in adults. The kit for detecting MND in adults provided by this invention contains primer sequences for amplifying miR-98-5p. This invention also provides a kit for distinguishing MND from other kidney diseases in adults, the kit containing primer sequences for detecting the relative expression levels of miR-98-5p, miR-204-5p, and / or miR-194-5p in urine samples. Using the kit provided by this invention for the diagnosis of MND, from morning urine collection to obtaining the final result, only 8-12 hours are required, saving patients valuable time and facilitating early treatment and benefit.

This invention provides a combination of biomarkers for predicting thyroid cancer metastasis and their applications. Specifically, this invention provides the use of genes, mRNAs, cDNAs, proteins, or detection reagents thereof for a combination of risk biomarkers for assessing thyroid cancer metastasis, for the preparation / establishment of diagnostic reagents or kits / devices for assessing the risk of thyroid cancer metastasis. Studies have shown that the combination of thyroid cancer metastasis risk biomarkers can serve as biomarkers for early assessment of thyroid cancer metastasis in patients, exhibiting high sensitivity and specificity. It can rapidly diagnose thyroid cancer metastasis at a relatively early stage of disease progression, providing strong support for early treatment intervention.

The invention provides a marker combination for predicting thyroid cancer metastasis and application thereof. Specifically, the invention provides application of a gene, mRNA, cDNA and protein of the risk marker combination for thyroid cancer metastasis judgment or a detection reagent of the gene, the mRNA, the cDNA and the protein, and is used for preparing / establishing a diagnostic reagent or a kit / equipment for judging the thyroid cancer metastasis occurrence risk. Researches show that the thyroid cancer metastasis risk marker combination can be used as a marker for early judgment of thyroid cancer metastasis of a thyroid cancer patient, has high sensitivity and specificity, can quickly diagnose thyroid cancer metastasis at a relatively early disease progress stage, and provides powerful assistance for early treatment intervention of diseases.

The present application relates to the field of medicine, and more particularly to a kind of drug composition for continuing sinew and setting bone and application thereof, the traditional Chinese medicine composition includes the following components by weight fraction: Rhizoma Drynariae 10-20 parts, Fructus Corni 5-15 parts, Lobelia 5-15 parts, crab shell 5-15 parts, snakeberry 5-15 parts, fresh Oxalis 40-60 parts, sugar candy 15-25 parts, the traditional Chinese medicine composition of the present application is suitable for preparing early treatment of closed fracture external medicine, with the characteristics of curative effect, safe use, compatibility science, dosage form optimization. With "dynamic and static combination, cold and warm counteraction, clearing and tonifying combination" as the core of formula, it has the effects of tonifying kidney and strengthening bone, promoting blood circulation to remove blood stasis, clearing heat and resolving toxin, removing dampness and swelling, swelling and pain relief, continuing sinew and setting bone; It also has simple preparation process, can effectively retain fresh medicine active ingredients, and use specific steps to combine dry powder, fresh medicine juice and sugar candy organically, to make paste with strong adhesion, good moisture retention, easy to apply and can release drug efficacy for a long time.

This disclosure relates generally to and, more particularly, to assessment of PCOS. Polycystic ovarian syndrome (PCOS) is a hormonal disorder common among women of reproductive age that causes infertility and affects overall health of the woman. As PCOS is common and curable cause of infertility, an efficient early screening to assess a potential risk of PCOS can ensure early treatment. The current state-of-the-art techniques include diagnostic, screening solutions, imaging techniques which are invasive, complex, expensive. The disclosure is a supervised machine learning algorithm on the samples of individuals to arrive at a panel of biological features / indicators / markers / signatures that can accurately stratify / classify / group individuals into ‘PCOS’ and ‘healthy’ based upon the differences in the composition of the gut / oral microbial communities.

The application provides a baby motion posture analysis system for assisting in diagnosing cerebral palsy, and belongs to the technical field of medical measurement. The system comprises a video processing module, an image processing module, a data processing module, an analysis module, a discrimination module and a user graphical interface module, objectively evaluates the motion function in the early brain development of babies and infants, and assists doctors in diagnosing whether the babies and infants have cerebral palsy. The application has the following advantages: 1. The risk of cerebral palsy of a baby to be measured can be determined by using the whole body motion video of the baby, so that early treatment and rehabilitation of high-risk babies can be realized; 2. The analysis module is based on the statistical principle, and a more reliable prediction classification feature vector is obtained, so that the correlation between the motion characteristics of babies and neurodevelopmental abnormalities can be quantitatively studied; and 3. The discrimination module is based on the key point time window sequence decision threshold strategy and the symmetric decision tree algorithm, so that the accuracy and generalization of the prediction classification are improved.

The invention discloses a urine metabolism marker combination for diagnosing kidney cancer stages and application of the urine metabolism marker combination, and belongs to the field of kidney cancer markers. The urine metabolism marker combination for diagnosing the stages of the kidney cancer is prepared from cis-3-hexenol glucoside, 3-hydroxy-3-methyl valeric acid, N-acetyl-L-glutamic acid and high carnosine. The urine metabolism marker combination has high specificity, high sensitivity and non-invasiveness when being used for diagnosing the kidney cancer by stages, so that subjects can conveniently and safely receive detection, and the urine metabolism marker combination is suitable for screening and detection of large-scale common people and is beneficial to early screening, early diagnosis and early treatment of the kidney cancer.

Compositions and methods for treating or preventing non-alcoholic steatohepatitis (NASH). In one aspect, the disclosed methods involve targeting macrophage receptors referred to as T cell-containing immunoglobulin and mucoprotein domain 4 (TIM4). The compositions and methods disclosed herein can be used as disease modification therapies to enable the treatment of NASH and related conditions and improvement of clinical outcomes at the early stage of disease progression.

Blood and lung infections are a worldwide health problem with approximately five million deaths each year. Early treatment could help save lives, but better tests to identify these infections are needed. This invention identifies pathogens, particularly those that are resistant to antibiotics, faster. This invention allows for appropriate antibiotic treatment at an earlier time point. Data from deep RNA sequencing of human blood is used to create a faster diagnostic test for infections and associated antimicrobial resistance.

The system according to this embodiment aims to monitor the health status of elderly people in real time and to detect and respond to abnormalities at an early stage. [Solution] The system according to the embodiment comprises a data collection unit, an analysis unit, a detection unit, and a response unit. The data collection unit monitors the health status of elderly people in real time. The analysis unit analyzes the data collected by the data collection unit. The detection unit detects abnormalities based on the data analyzed by the analysis unit. The response unit takes action for early treatment or accident prevention based on the abnormalities detected by the detection unit.

The invention discloses application of terazosin in preparation of drugs or health care products for preventing and / or treating aortic dissection, and relates to the technical field of medicines. Animal test and clinical research are carried out on the current clinical common drug terazosin, and the result shows that the small dose of terazosin can effectively prevent and treat the aortic dissection, so that important technical support is provided for early treatment or prevention of aortic related diseases. Experimental and clinical research results also prove that the terazosin with the dosage of 0.5 mg has a good effect in the aspects of improving the vascular elasticity and reducing the vascular pulse wave conduction velocity, the dosage can be greatly reduced, the medication cost can be saved, and the medical burden of a patient can be relieved. Meanwhile, due to the fact that the dosage of terazosin used in the human body is extremely low, adverse side effects related to terazosin are basically eradicated.

The invention discloses a lung cancer classification and prediction method based on deep learning, and the method comprises the steps: collecting a first data set of a lung cancer patient, carrying out the preprocessing and differentiation analysis of the first data set, and obtaining a second data set; integrating the second data set; constructing a convolutional neural network model; and evaluating the stability and generalization ability of the model through cross validation, dividing the second data set into a training set and a test set, and inputting the training set and the test set into the model for training and verification. The diagnosis accuracy is improved, the accuracy of early diagnosis of the lung cancer is remarkably improved by integrating multi-omics data, and early treatment and survival rate improvement of a patient are assisted; personalized treatment is supported, a precise treatment scheme based on molecular characteristics of a patient is provided, medical resource allocation is optimized, and unnecessary medicine use and side effects are reduced; the medical cost is reduced, through early diagnosis and reduction of manual analysis time, the treatment complexity and cost are reduced, and meanwhile, medical system reform and social and economic burden reduction are promoted.

The application provides application of a modified form of LDHA, LDHA S319 phosphorylation, as a biomarker in preparation of a tumor diagnosis reagent, and provides a kit for quantitatively or semi-quantitatively detecting a protein, which contains an antibody capable of specifically combining with LDHA S319 phosphorylation. The application can more effectively preliminarily evaluate and predict whether a subject has a tumor by detecting the expression level of LDHA S319 phosphorylation. The application can help improve the diagnosis accuracy of the tumor and provide an important basis for early treatment of the patient. The application also provides application of the antibody of LDHA S319 phosphorylation in preparation of a tumor diagnosis kit.

The invention belongs to the technical field of biological medicine, provides a method for constructing a biosafety mouse bone tuberculosis model based on mycobacterium smegmatis, and evaluates that under the condition of a standard biosafety level (BSL)-1, the mycobacterium smegmatis induces local and disseminated bone infection through three infection pathways, and the bone tuberculosis model has the advantages that the bone tuberculosis is induced by the mycobacterium smegmatis through three infection pathways; results show that the mouse model for intracentral injection administration of the three infection pathways is closer to the latent progress of human bone tuberculosis. The mouse model based on the mycobacterium smegmatis provides a simple and reliable platform related to immunopathology for exploring host-pathogen dynamics, immunologically-driven bone destruction and early treatment tests.